Zhangdayong

Prof. Zhang has held various prominent positions, including Dean of the Lianyungang Research Institute at China Pharmaceutical University, Deputy Dean of the School of Science, and Deputy Director of the National Lianyungang Economic and Technological Development Zone Management Committee. Additionally, he served as Director and Chief Engineer of Inner Mongolia Huayang Chemical Co., Ltd., and as Executive Director and General Manager of Shandong Kailong Biotechnology Co., Ltd. He is also a Visiting Professor at the Jiangsu Agrochemicals Engineering Technology Research Center. His professional affiliations include being a member of the Chinese Peasants' and Workers' Democratic Party and a recognized talent training object of the 'Six Talent Peaks' program in Jiangsu Province. He has contributed as an expert in the evaluation of degree and graduate education for the Ministry of Education, as well as in the evaluation processes for the National Natural Science Foundation of China. Furthermore, he has been involved in evaluating major scientific and technological projects during the 12th and 13th Five-Year Plans, and serves as a national veterinary drug evaluation expert for the Ministry of Agriculture. His past roles also encompass Deputy Director of the National Lianyungang Economic and Technological Development Zone, Deputy Director of the Management Committee of Wuxi (Mashan) National Life Science Park, Assistant Director of the Management Committee of Taihu National Tourism Resort, and Associate Professor at the School of Chemistry and Environmental Sciences at Nanjing Normal University. He has presided over numerous provincial and national research projects, as well as collaborative research and development initiatives with enterprises. He has edited and reviewed articles for a variety of domestic and international core journals, including those indexed in SCI. He has published over 130 SCI research papers and has applied for more than 50 invention patents. His teaching portfolio includes undergraduate, master's, and doctoral courses such as Drug Design, Selected Theories of Advanced Medicinal Chemistry, and Pharmacostereochemistry. Currently, he leads a research team of nearly 30 master's and doctoral students, who are primarily focused on basic research, application development, and the industrial mass production of pharmaceuticals, pesticides, and their intermediates.

1. Hao Yin; Menghan Zhang; Congying Gu; Zhenyu Li; Chenyan Hao; Junhui Wang; Lulu Tian;  Kang Xu; Xiangyu Hu; Liqin Ming; Min Zhang; Zhanbo Wang; Yong Yang*; Dayong Zhang*; Beiying Dai*. Discovery of Novel 2‑Oxoacetamide Derivatives as B3GAT3 Inhibitors for the Treatment of Hepatocellular Carcinoma., J Med Chem, 2024, 67, 10743−10773.

2. Menghan Zhang; Yushi Ding; Mengkang Gao; Xiaolin Lu; Jun Tan; Fei Yu; Congying Gu; Lujun Gu; Xiameng Ren; Chenyan Hao; Liqin Ming; Kang Xu; Wenhao Mao; Yuqing Jin; Min Zhang; Linjun You;, Zhanbo Wang; Yuanyuan Sun; Jingwei Jiang; Yong Yang*; Dayong Zhang*; Xinying Tang*. Discovery of novel N-(anthracen-9-ylmethyl) benzamide derivatives as ZNF207 inhibitors promising in treating glioma., J Med Chem, 2024, 67(5): 3909-3934.

3. Chengjuan Chen, Yuan Yin, Gaona Shi, Yu Zhou, Shuai Shao, Yazi Wei, Lei Wu, Dayong Zhang*, Lan Sun*, Tiantai Zhang*. A highly selective JAK3 inhibitor is developed for treating rheumatoid arthritis by suppressing γc cytokine-related JAK-STAT signal., Sci Adv, 2022, 8(33): eabo4363.

4. Yue Wang; Menghan Zhang; Ran Bi; Yali Su; Fei Quan; Yanting Lin; Chongxiu Yue; Xinmeng Cui; Qixiang Zhao; Siliang Liu; Yong Yang*; Dayong Zhang*; Qihua Cao*; Xinghua Gao*. ACSL4 deficiency confers protection against ferroptosis-mediated acute kidney injury., Redox Biol, 2022, 51: 102262.

5. Ke Wang, Yang-Chang Wu, Juan-Cheng Yang, Meng-Han Zhang, Mohamed EI-Shazly, Da-Yong Zhang^*, Xiao-Ming Wu. Synthesis of Novel 3,19-Dihydroxyjolkinolides and Related Derivatives Starting from Andrographolide[J]. Synthesis, 2016, 48: 2245-2254.

6. Liangwei Zhang, Xiangdong Li, Yuanhong Liu^*, Da-Yong Zhang^*. Palladium- catalyzed highly efficient synthesis of functionalized indolizines via cross-coupling /cycloisomerization cascade[J]. Chem. Commu., 2015, 51(30): 6633-6636.

7. Yan Luo, Ke Wang, Meng-han Zhang, Da-Yong Zhang^*, Yang-chang Wu, Xiao-ming Wu, Wei-yi Hua. Synthesis of new ent-labdane diterpene derivatives from andrographolide and evaluation on cytotoxic activities[J]. Bioorg. Med. Chem. Lett., 2015, 25: 2421-2424.

8. Yang Li, Ke Wang, Bin Zhou, Yong Tang, Da-yong Zhang*, Yang-Chang Wu,Wei-yi Hua, Xiao-ming Wu. A new ent-kaurenoide agent CPUK02 can notably inhibit tumor growth through induction of the cell apoptosis. Chin. J Nat. Med., 2012, 10(6): 429-435.

9. Yao-fu Zeng, Jia-qiang Wu, Lian-yong Shi, Ke Wang, Bin Zhou, Yong Tang, Da-yong Zhang^*,Yang-chang Wu, Wei-yi Hua, Xiao-ming Wu. Synthesis and evaluation of cytotoxic effects of novel α-methylenelactone tetracyclic diterpenoids[J]. Bioorg. Med. Chem. Lett., 2012, 22: 1922-1925. 

10. Lian-Yong Shi, Jia-Qiang Wu, Da-Yong Zhang*, Yang-Chang Wu, Wei-Yi Hua, Xiao-Ming Wu. Efficient Synthesis of Novel Jolkinolides and Related Derivatives Starting from Stevioside[J]. Synthesis, 2011, 23: 3807-3814.

11. Jing Li, Dayong Zhang*, Xiaoming Wu. Synthesis and biological evaluation of novel exo-methylene cyclopentanone tetracyclic diterpenoids as antitumor agents [J]. Bioorg. Med. Chem. Lett., 2011, 21: 130-132. 

12. XUE Jian-Yue, ZHOU Bin, ZHANG Da-yong*, WU Xiao-ming. Research progress of the biological characteristics of IкB kinase and its inhibitors [J]. Acta Pharma. Sinica, 2011, 46(3): 253-260.

13. ZHANG Da-yong*, SHI Lian-yong, WU Xiao-ming. Progress in ent-Abietane Euphorbiae Diterpene Lactones [J]. Chin. J. Org. Chem., 2009, 29(2): 188-196.

14. WANG Quan, ZHANG Da-yong*, WU Xiao-ming. Research progress of bioactivities of plant-derived macrocyclic diterpenoid compounds [J]. J. Chin. Pharm. Uni., 2009, 40(5): 474-480.

15. TANG Yong, ZHANG Da-yong*, WU Xiao-ming. Progress in small-molecule inhibitors of Bcl-2 family proteins [J]. Acta Pharma. Sinica, 2008, 37(7): 237-242.

ZHANG Da-yong, LI Zi-yuan, SHI Lian-yong, WU Xiao-ming, HUA Wei-yi. Advances in research on cytotoxical activity of ent-kaurane diterpenoids [J]. Chin. J. Org. Chem., 2008, 28(11): 1911-1917.

1. Synthesis of novel ent-kauriene-type glycosides and preliminary evaluation of their NF-κB inhibitory activity, National Natural Science Foundation of China (81172934), 2012.1-2015.12.

2. Synthesis of alkyolide diterpenoid analogues and their IκB kinase inhibitory activity, National Natural Science Foundation of China (30973607), 2010.1-2012.12.

3. Synthesis of ENT-kauri analogue from steviol or isosteviol and its anti-tumor activity, Six Talent Peaks Project (Y092003) of Jiangsu Province, 2009.1-2012.12.

4. Synthesis of Jolkinolide analogues and their antitumor activity, Talent Introduction Fund (211091), China Pharmaceutical University, 2006.9-2008.9.

5. Research on ATPT, a class of new antihypertensive drugs (2009ZX09102-036), National Major New Drug Creation Science and Technology Major Project Eleventh Five-Year Plan, 2009.1-2010.12.

6. Research on ZLJ-601, a new anti-atherosclerotic drug (2009ZX09103-098), National Major New Drug Creation Science and Technology Major Project Eleventh Five-Year Plan, 2009.1-2010.12.

7. Research on the synthesis and biological activity of pysulfuron, Science and Technology Research Project of Jiangsu Provincial Department of Science and Technology (2005103SB9B555), 2006.6-2008.12.

8. Synthesis of lupusin lactone and its anti-tumor activity, Graduate Innovation Project of Jiangsu Provincial Department of Education, 2010.1-2012.1.

9. Presided over dozens of joint (cooperative) research projects (omitted).